NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced its quarterly earnings results on Monday, November, 4th. The company reported ($0.67) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.84) by $0.17. The firm earned $13.15 million during the quarter, compared to analyst estimates of $1.61 million. Karyopharm Therapeutics had a negative return on equity of 187.25% and a negative net margin of 909.24%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 analysts have issued twelve-month target prices for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $37.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

News coverage about KPTI stock has trended extremely negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a decrease in short interest in December. As of December 31st, there was short interest totalling 9,570,000 shares, a decrease of 6.8% from the December 15th total of 10,270,000 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is presently 7.6 days. Currently, 17.2% of the shares of the company are short sold. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Caladrius Biosciences (CLBS), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH) and Novavax (NVAX).

Karyopharm Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Private Capital Advisors Inc. (0.17%), Campbell & CO Investment Adviser LLC (0.06%) and First Midwest Bank Trust Division (0.04%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $16.50.

Karyopharm Therapeutics has a market capitalization of $1.04 billion and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]